Peptide Library

Human study PLS-00169

MALDI imaging mass spectrometry analysis-A new approach for protein mapping in multiple sclerosis brain lesions.

Other design · 12 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • MALDI imaging mass spectrometry analysis-A new approach for protein mapping in multiple sclerosis brain lesions.primary · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2016-07-01 · PMID 27461358 · DOI

Design and participants

Design
Other design
Population
Brain tissue sections from multiple sclerosis patients, covering normal-appearing white matter, grey matter and lesions with different extents of remyelination.
Conditions
Multiple sclerosis
Setting
Laboratory analysis of brain tissue (pilot study).
Planned enrollment (registry)
Not reported
Enrolled
12
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; the compound was not administered.

    The authors concluded (paraphrased): MALDI-IMS can map proteins in brain parenchyma and MS lesions. Thymosin beta-4, located mainly at lesion rims, may be a marker involved in MS pathogenesis and/or remyelination.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta-4 was only measured as an endogenous protein in tissue; it was never administered to participants.
    • small or imprecise: Pilot study profiling brain slides from only 12 multiple sclerosis patients.
    • abstract only: Only the PubMed abstract is available in the record; full methods and results are not provided.
    • no control group: Descriptive tissue profiling pilot with no comparison group and no intervention given.
    • inappropriate endpoint: Outcome is a tissue biomarker distribution, not a clinical or safety outcome for administered compound.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 27461358, abstract (sentence 10) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 27461358, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 27461358, abstract (sentence 9) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 27461358, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).